| Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4-and SDF-1-deficient mice Q Ma, D Jones, PR Borghesani, RA Segal, T Nagasawa, T Kishimoto, ... Proceedings of the National Academy of Sciences 95 (16), 9448-9453, 1998 | 2060 | 1998 |
| Differentiation and reversal of malignant changes in colon cancer through PPARγ P Sarraf, E Mueller, D Jones, FJ King, DJ DeAngelo, JB Partridge, ... Nature medicine 4 (9), 1046-1052, 1998 | 1257 | 1998 |
| The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment Q Ma, D Jones, TA Springer Immunity 10 (4), 463-471, 1999 | 864 | 1999 |
| Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate E Jabbour, H Kantarjian, D Jones, M Talpaz, N Bekele, S O'brien, X Zhou, ... Leukemia 20 (10), 1767-1773, 2006 | 508 | 2006 |
| BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia JA Woyach, AS Ruppert, D Guinn, A Lehman, JS Blachly, A Lozanski, ... Journal of Clinical Oncology 35 (13), 1437, 2017 | 493 | 2017 |
| Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia E Estey, G Garcia-Manero, A Ferrajoli, S Faderl, S Verstovsek, D Jones, ... Blood 107 (9), 3469-3473, 2006 | 473 | 2006 |
| Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia F Ravandi, JE Cortes, D Jones, S Faderl, G Garcia-Manero, ... Journal of clinical oncology 28 (11), 1856, 2010 | 471 | 2010 |
| MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation FJ Giles, J Cortes, D Jones, D Bergstrom, H Kantarjian, SJ Freedman Blood 109 (2), 500-502, 2007 | 468 | 2007 |
| Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin F Ravandi, E Estey, D Jones, S Faderl, S O'Brien, J Fiorentino, S Pierce, ... Journal of Clinical Oncology 27 (4), 504, 2009 | 461 | 2009 |
| First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic … F Ravandi, S O'Brien, D Thomas, S Faderl, D Jones, R Garris, S Dara, ... Blood, The Journal of the American Society of Hematology 116 (12), 2070-2077, 2010 | 402 | 2010 |
| Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors J Cortes, E Jabbour, H Kantarjian, CC Yin, J Shan, S O'Brien, ... Blood, The Journal of the American Society of Hematology 110 (12), 4005-4011, 2007 | 351 | 2007 |
| Marek disease virus encodes a basic-leucine zipper gene resembling the fos/jun oncogenes that is highly expressed in lymphoblastoid tumors. D Jones, L Lee, JL Liu, HJ Kung, JK Tillotson Proceedings of the National Academy of Sciences 89 (9), 4042-4046, 1992 | 344 | 1992 |
| Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate J Cortes, M Talpaz, S O'Brien, D Jones, R Luthra, J Shan, F Giles, ... Clinical Cancer Research 11 (9), 3425-3432, 2005 | 329 | 2005 |
| Lenalidomide therapy in myelofibrosis with myeloid metaplasia A Tefferi, J Cortes, S Verstovsek, RA Mesa, D Thomas, TL Lasho, ... Blood 108 (4), 1158-1164, 2006 | 314 | 2006 |
| Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia JE Cortes, D Jones, S O'Brien, E Jabbour, F Ravandi, C Koller, ... Journal of Clinical Oncology 28 (3), 398, 2010 | 312 | 2010 |
| Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase JE Cortes, D Jones, S O'Brien, E Jabbour, M Konopleva, A Ferrajoli, ... Journal of Clinical Oncology 28 (3), 392, 2010 | 308 | 2010 |
| Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome–positive chronic-phase chronic … HM Kantarjian, JE Cortes, S O'Brien, R Luthra, F Giles, S Verstovsek, ... Blood 104 (7), 1979-1988, 2004 | 267 | 2004 |
| Elective cancer surgery in COVID-19–free surgical pathways during the SARS-CoV-2 pandemic: an international, multicenter, comparative cohort study JC Glasbey, D Nepogodiev, JFF Simoes, O Omar, E Li, ML Venn, PGDME, ... Journal of Clinical Oncology 39 (1), 66-78, 2021 | 266 | 2021 |
| The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia D Jones, RJ Benjamin, A Shahsafaei, DM Dorfman Blood, The Journal of the American Society of Hematology 95 (2), 627-632, 2000 | 246 | 2000 |
| Philadelphia chromosome–positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis CP Soupir, JA Vergilio, PD Cin, A Muzikansky, H Kantarjian, D Jones, ... American journal of clinical pathology 127 (4), 642-650, 2007 | 236 | 2007 |
